Bora Pharmaceuticals Completes Acquisition of MacroGenics’ Rockville Mfg. Ops

Bora Pharmaceuticals has completed its acquisition of MacroGenics, Inc.’s GMP manufacturing operations, including its biologics drug substance facility in Rockville, MD and an associated warehousing center in Frederick, MD, for $122.5 million through its subsidiary Bora Biologics USA, LLC. Upon closing, Bora signed a long-term CDMO service agreement with MacroGenics. 

With the close of the transaction, Bora Group’s biologics CDMO franchise, Bora Biologics, now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active U.S. sites: Rockville, MD and San Diego, CA, and one development facility in Zhubei, Taiwan. 

“This acquisition establishes a U.S. biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply,” said Bobby Sheng, Chairman and CEO of Bora Group. “As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with U.S.-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities.” 

With the addition of the Rockville facility, Bora Biologics supports more than 4 active commercial programs, with more than 120 completed GMP batches and supply into multiple global markets including the U.S., EU, Japan, Canada and the UK with fully integrated QC and analytical capabilities. 

Bora Group intends to integrate its U.S. drug substance (DS) capabilities with its existing sterile drug product (DP) capabilities over the next 12 to 18 months, offering a fully integrated development-through-commercial biologic services.